FDA Vaccine Advisors Put Manufacturers On Notice: New Flu Vax Licensing Requirements May Be Coming
Executive Summary
The US FDA and its vaccine advisors said manufacturers need to start thinking about the types of studies needed if a major change is made to the quadrivalent flu vaccine by swapping out the B/Yamagata lineage for a second lineage of another flu strain.
You may also be interested in...
Sayonara, Yamagata: US Seasonal Flu Vaccines Shift From Quadrivalent To Trivalent For 2024-2025
New US formulations will contain only one B virus antigen after shedding the B/Yamagata component, a strain that has not been detected in circulation since March 2020. However, some US manufacturers will continue to produce quadrivalent vaccine for use in other countries, which have been slower to transition to trivalent.
US FDA Wants Global COVID-19 Vaccine Update System, But Says May Not Be Possible
The agency’s Vaccines and Related Biological Products Advisory Committee will consider simplifying and harmonizing the vaccine composition, as well as formalizing a system for likely annual US updates.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.